200 related articles for article (PubMed ID: 36570409)
1. Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia.
Low JL; Lim E; Bharwani L; Wong A; Wong K; Ow S; Lim SE; Lee M; Choo J; Lim J; Chan G; Walsh RJ; Muthu V; Ngoi N; Chong W; Tan SH; Lee SC
Ther Adv Med Oncol; 2022; 14():17588359221139678. PubMed ID: 36570409
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.
Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC
Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172
[TBL] [Abstract][Full Text] [Related]
3. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
[TBL] [Abstract][Full Text] [Related]
4. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
Smyth EN; Beyrer J; Saverno KR; Hadden E; Abedtash H; DeLuca A; Lawrence GW; Rybowski S
Drugs Real World Outcomes; 2022 Dec; 9(4):681-693. PubMed ID: 36097254
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M
JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
7. Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer.
Sathe C; Accordino MK; DeStephano D; Shah M; Wright JD; Hershman DL
Breast Cancer Res Treat; 2023 Jul; 200(1):85-92. PubMed ID: 37157005
[TBL] [Abstract][Full Text] [Related]
8. Retrospective registry of patients with locally advanced/metastatic HR
Chavarría Piudo N; Blancas I; González Flores E; Henao Carrasco F; López Álvarez P; Morales Pancorbo D; Gámez Casado S; Lomas Garrido MC; Rodríguez García JM; Martínez Guisado A; Sánchez Vega A; Ruíz Borrego M
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38831191
[TBL] [Abstract][Full Text] [Related]
9. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
10. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
11. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD
Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421
[TBL] [Abstract][Full Text] [Related]
12. RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.
Petracci F; Abuin GG; Pini A; Chacón M
Ecancermedicalscience; 2020; 14():1058. PubMed ID: 32582373
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
Beddok A; Mouren V; Cottu P; Laki F; Fourquet A; Kirova Y
Int J Cancer; 2023 Oct; 153(7):1386-1396. PubMed ID: 37381597
[TBL] [Abstract][Full Text] [Related]
14. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
15. Case report:
Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
Zattarin E; Mariani L; Menichetti A; Leporati R; Provenzano L; Ligorio F; Fucà G; Lobefaro R; Lalli L; Vingiani A; Nichetti F; Griguolo G; Sirico M; Bernocchi O; Marra A; Corti C; Zagami P; Agostinetto E; Jacobs F; Di Mauro P; Presti D; Sposetti C; Giorgi CA; Guarneri V; Pedersini R; Losurdo A; Generali D; Curigliano G; Pruneri G; de Braud F; Dieci MV; Vernieri C
Ther Adv Med Oncol; 2023; 15():17588359231204857. PubMed ID: 38130467
[TBL] [Abstract][Full Text] [Related]
17. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
Cook MM; Al Rabadi L; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
Oncologist; 2021 Feb; 26(2):101-106. PubMed ID: 33230905
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience.
Edman Kessler L; Wiklander O; Hamberg E; Bergh J; Foukakis T; Matikas A
Acta Oncol; 2020 Nov; 59(11):1382-1387. PubMed ID: 32783667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
